Clinical trial NCT00874471: Uveitis Gene-Expression Profiling
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Uveitis
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
First posted: 2009-04-02
Enrollment: 280
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals suffering from selected subtypes of uveitis, individuals suffering from selected autoimmune disease and healthy individuals.

Brief summary: Uveitis is a group of troublesome diseases that collectively represent a cause of blindness comparable to diabetes. Most forms of uveitis are either infectious or immune-mediated. The investigators propose to create a data base on peripheral blood gene expression for patients with 3 of the most important diseases associated with uveitis: ankylosing spondylitis, sarcoidosis, and Behcet's disease. The investigators will quantitatively measure the expression of consistent alteration in peripheral blood from patients with more than 40,000 gene sequences using microarray gene chip technology. This approach is known to detect systemic immune-mediated disease. The investigators will use this data base to:

1. Determine if patients with uveitis and ankylosing spondylitis, sarcoidosis, or Behcet's can be distinguished from a normal population or controls with the same systemic disease but no history of uveitis
2. Determine if the profile of gene expression can distinguish infectious or idiopathic forms of uveitis from patients with spondylitis, sarcoidosis, or Behcet's
3. Determine how this gene profile changes over time as episodic disease such as spondylitis or Behcet's activates or remits
4. Correlate the changes in gene expression with the prognosis of the ocular inflammatory process.

The creation of a gene expression data base for patients with uveitis has the potential to clarify the pathogenesis of disease, establish new diagnostic tools, and provide a means for predicting prognosis.


Eligibility criteria: Inclusion Criteria:

* The study group will include patients aged 21 years or older attending the Uveitis Clinic at the Casey Eye Institute at OHSU who have uveitis of the following subtypes:

  1. ankylosing spondylitis
  2. sarcoidosis
  3. Behçet's disease
  4. toxoplasmosis
  5. herpetic acute retinal necrosis; AND
  6. idiopathic uveitis
* Another group of patients, also aged 21 years or more, with the following diseases but no uveitis, will be recruited from the Rheumatology Clinic at OHSU as follows:

  1. ankylosing spondylitis
  2. sarcoidosis; AND
  3. Behçet's disease
* The study group will also include 30 normal control volunteers aged 21 years or older.

Exclusion Criteria:

* Special/vulnerable subject populations (e.g., mentally impaired persons and children) will not be enrolled.

Primary outcomes:
measure: Correlation of blood transcriptome with form of uveitis
timeFrame: time of office visit for disease evaluation
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: Oregon Health & Science University
state: Oregon
Study officials:
affiliation: Oregon Health and Science University
name: James Rosenbaum, MD
role: PRINCIPAL_INVESTIGATOR
References: